Prematching cohorts | Postmatching cohorts | Standardised | |||
Dual eligible | Dual eligible | ||||
No | Yes | No | Yes | ||
n (%) | n (%) | n (%) | n (%) | Differences | |
N | 16 259 | 5414 | 5312 | 5312 | |
Age (years) | |||||
<65 | 1439 (8.85) | 1869 (34.52) | 1559 (29.35) | 1525 (28.71) | −0.12 |
65–74 | 6946 (42.72) | 1794 (33.14) | 1961 (36.92) | 1944 (36.60) | 0.06 |
75–84 | 5564 (34.22) | 1193 (22.04) | 1235 (23.25) | 1269 (23.89) | 0.07 |
85+ | 2310 (14.21) | 558 (10.31) | 557 (10.49) | 574 (10.81) | 0.10 |
Male | 9675 (59.51) | 2718 (50.20) | 2783 (52.39) | 2827 (53.22) | −0.06 |
White | 14 256 (87.68) | 3668 (67.75) | 3588 (67.55) | 3616 (68.07) | 0.20 |
Medication use | |||||
ACE inhibitor | 13 561 (83.41) | 4600 (84.96) | 4527 (85.22) | 4500 (84.71) | −0.01 |
Anticoagulant | 2698 (16.59) | 814 (15.04) | 785 (14.78) | 812 (15.29) | 0.05 |
Aspirin | 11 887 (73.11) | 3855 (71.20) | 3729 (70.20) | 3734 (70.29) | −0.08 |
Beta blocker | 9854 (60.61) | 3355 (61.97) | 3324 (62.58) | 3276 (61.67) | −0.05 |
Platelet p2y12 inhibitors | 6703 (41.23) | 2313 (42.72) | 2175 (40.95) | 2169 (40.83) | 0.05 |
Statin | 11 466 (70.52) | 3769 (69.62) | 3612 (68.00) | 3641 (68.54) | 0.09 |
COPD | 4101 (25.22) | 1843 (34.04) | 1645 (30.97) | 1629 (30.67) | 0.07 |
Diabetes | 7481 (46.01) | 3013 (55.65) | 3172 (59.71) | 3073 (57.85) | −0.19 |
Rural | 3726 (22.92) | 1588 (29.33) | 1499 (28.22) | 1460 (27.48) | 0.08 |
Smoking status | |||||
Never | 3679 (22.63) | 1196 (22.09) | 1407 (26.49) | 1406 (26.47) | −0.02 |
Past | 8695 (53.48) | 1911 (35.30) | 2038 (38.37) | 2067 (38.91) | −0.09 |
Current | 3885 (23.89) | 2307 (42.61) | 1867 (35.15) | 1839 (34.62) | 0.09 |
CLI | 10 652 (65.51) | 3959 (73.13) | 3974 (74.81) | 3983 (74.98) | |
Claudication | 5607 (34.49) | 1455 (26.87) | 1338 (25.19) | 1329 (25.02) | 0.11 |
Median household income of zip code | $58 125 (25 138) | $48 398 (21 034.2) | $48 940 (18 999) | $49 406 (21 236) | −0.16 |
CLI, critical limb ischaemia; COPD, chronic obstructive pulmonary disease.